Enterprise Value

3.771B

Cash

876.7M

Avg Qtr Burn

-39.6M

Short % of Float

18.71%

Insider Ownership

2.83%

Institutional Own.

-

Qtr Updated

12/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Evrysdi (riskiplam) Details
Spinal muscular atrophy

Approved

Quarterly sales

Emflaza (deflazacort) Details
Duchenne muscular dystrophy

Approved

Quarterly sales

Upstaza (PTC-AADC) Details
Aromatic L-amino acid decarboxylase deficiency

BLA

Submission

Translarna (ataluren) Details
Duchenne muscular dystrophy

NDA

Resubmission

Vatiquinone (PTC743) Details
Friedreich’s Ataxia

NDA

Submission

NDA

Submission

Utreloxastat Details
Amyotrophic lateral sclerosis

Phase 2

Data readout

PTC518 Details
Huntington's disease

Phase 2

Data readout

Vatiquinone (PTC743) Details
Epilepsy, Mitochondrial disease

Failed

Discontinued

Failed

Discontinued